<DOC>
	<DOCNO>NCT00772473</DOCNO>
	<brief_summary>To assess CGRP level saliva evolution migraine .</brief_summary>
	<brief_title>Correlation Calcitonin Gene-Related Peptide ( CGRP ) Levels Saliva With Evolution Attack Migraine</brief_title>
	<detailed_description>The release CGRP assume initiate early migraine process increase headache intensifies . Levels CGRP measure premonitory , mild , moderate , severe phase single migraine attack compare baseline value determine subject headache free . Understanding clinical evolution migraine CGRP release may significant implication acute treatment .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<criteria>1 . Ability read , understand , sign inform consent 2 . Subject age 18 65 , either male female 3 . Negative pregnancy test childbearing potential . 4 . Adequate birth control approve investigator childbearing potential 5 . Subjects must fulfill criterion IHS migraine ( 1.1 1.2 ) history 16 migraine per month within past 3 month least 15 headache free day though previous three month time period 1 . Pregnant breast feed 2 . Presence condition symptom would knowingly alter content saliva 3 . Presence medical disease condition would interfere conduct study 4 . Current use medication would contraindicate patient take triptan medication treatment migraine symptom , ie . MAO inhibitor , lithium , methyergonovine , methysergide , ergotaminecontaining product 5 . Use migraine preventive medication three month prior screen 6 . History drug alcohol abuse would interfere study 7 . Any pathology salivary gland sialadenitis ( e.g. , Sjorgen 's syndrome , viral bacterial sialadenitis , obstructive sialadentitis ) 8 . History hypersensitivity allergy triptan medication 9 . Presence diabetes , salivary gland tumor , liver disease , alcoholism , neuropathy 10 . More 15 day per month headache within past 3 month 11 . Participation another investigative drug study within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>